Apomorphine Hydrochloride Injection Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 10 mg/mL, 20 mg/mL
Reference Brands: Apokyn (USA)
Category:
Neurology
Apomorphine Hydrochloride Injection is available in Injection
and strengths such as 10 mg/mL, 20 mg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Apomorphine Hydrochloride Injection is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Apomorphine Hydrochloride Injection can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Apomorphine Hydrochloride, marketed under the brand name Apokyn, is a synthetic aporphine derivative that functions primarily as a non-selective dopamine agonist. It activates D2-like dopamine receptors and, to a lesser extent, D1-like receptors, making it effective in the management of motor symptoms associated with advanced Parkinson’s disease. Additionally, apomorphine exhibits antagonistic activity at 5-HT2 and α-adrenergic receptors, contributing to its overall pharmacological profile.
Although historically derived from morphine through chemical modification, apomorphine does not contain morphine, does not share its opioid structure, and does not bind to opioid receptors. Its name reflects its origin as a morphine decomposition product rather than any opioid activity. Apomorphine is used clinically to provide rapid relief of “off” episodes in Parkinson’s disease patients, restoring mobility and reducing symptoms such as bradykinesia, rigidity, and tremor. Administered subcutaneously or as a sublingual film, it acts quickly to improve motor function and is typically used under strict medical supervision due to potential side effects like nausea, hypotension, and sedation.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing